Sector
PharmaceuticalsOpen
₹1,406.9Prev. Close
₹1,412.95Turnover(Lac.)
₹3,339.73Day's High
₹1,428.6Day's Low
₹1,330.152 Week's High
₹1,42752 Week's Low
₹715.2Book Value
₹816.65Face Value
₹1Mkt Cap (₹ Cr.)
40,158.2P/E
27.99EPS
50.49Divi. Yield
0.1825 Aug 2023
12:00 AM
BookCloser
25 Aug 2023
12:00 AM
AGM
Announcement Date: 25 Aug, 2023
19 May 2023
12:00 AM
Dividend
Dividend Amount: 2.5
10 Jul 2024
12:00 AM
Board Meeting
Agenda : Audited Result
Here are some of the stocks that may see significant price movement today: Asian Paints, LTIMindtree, L&T Finance, Zee Entertainment, etc.
The sale will be conducted through the stock exchange mechanism, adhering to applicable legal requirements.
Here are some of the stocks that may see significant price movement today: SBI, Sula Vineyards, Zydus Lifesciences, Kesoram Industries, etc.
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 28.22 | 28.22 | 28.22 | 28.22 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 17,849.25 | 16,710.37 | 14,781.29 | 13,198.05 |
Net Worth | 17,877.47 | 16,738.59 | 14,809.51 | 13,226.27 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 7,567.93 | 6,712.63 | 6,403.23 | 7,989.23 |
yoy growth (%) | 12.74 | 4.83 | -19.85 | 30.64 |
Raw materials | -2,999.45 | -2,665.99 | -2,378.59 | -2,425.49 |
As % of sales | 39.63 | 39.71 | 37.14 | 30.35 |
Employee costs | -1,107.39 | -1,072.32 | -1,021.92 | -914.47 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | 1,869.86 | 1,516.09 | 1,218.82 | 2,789.34 |
Depreciation | -150.81 | -138.53 | -118.2 | -104.93 |
Tax paid | -294.31 | -180.09 | -204.47 | -412.28 |
Working capital | 463.74 | -1,507.52 | -180.36 | 1,492.86 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 12.74 | 4.83 | -19.85 | 30.64 |
Op profit growth | 44.93 | -3.21 | -53.51 | 64.2 |
EBIT growth | 20.49 | 25.73 | -52.08 | 65.02 |
Net profit growth | 21.77 | 33.53 | -52.61 | 44.21 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 11,635.46 | 11,431.94 | 12,174.2 | 10,806.03 | 10,397.23 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 11,635.46 | 11,431.94 | 12,174.2 | 10,806.03 | 10,397.23 |
Other Operating Income | 177.64 | 151.3 | 130.71 | 137.9 | 243.74 |
Other Income | 1,237.32 | 755.86 | 166.67 | 94.76 | 192.48 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,568.65 | 123.31 | 3,76,323.69 | 867.6 | 0.86 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,519.8 | 76.17 | 1,19,994.45 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,485.5 | 32.29 | 1,19,928.54 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,144.45 | 33.51 | 1,15,173.54 | 1,405.2 | 0.26 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,636 | 25.85 | 1,10,759.07 | 1,034.8 | 0.6 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman / Executive Director / M D / Promoter
Glenn Saldanha
Executive Director (Corporate)
Cheryl Pinto
Executive Director & Group CFO
V S Mani
Non Executive Director
B E Saldanha
Independent Non Exe. Director
Rajesh Desai.
Independent Non Exe. Director
Devendra Raj Mehta
Independent Non Exe. Director
Bernard Munos
Independent Non Exe. Director
Brian W Tempest
Independent Non Exe. Director
Sridhar Gorthi
Independent Non Exe. Director
Sona Saira Ramasastry
Independent Non Exe. Director
Dipankar Bhattacharjee
Independent Non Exe. Director
V R Iyer
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Glenmark Pharmaceuticals Ltd
Summary
Glenmark Pharmaceuticals Ltd was incorporated in November 18th, 1977. The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). It is engaged in the business of development, manufacture and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredients to regulated and semi-regulated markets. The company has several molecules in various stages of pre-clinical and clinical development primarily focused in the areas of Oncology, Respiratory and Dermatology. Its branded generics business has a significant presence in markets across emerging economies including India. The company has 14 manufacturing facilities across US, India, Argentina, Czech Republic and Switzerland. The generics business services the requirements of developed markets like the US and Western Europe. The API business sells products in over 80 countries including the US, various countries in the EU, South America and India.In the year 1979, the company entered dermatology market with the launch of Candid Cream. In the year 1980, they started exporting their products. In the year 1983, the company commissioned their first manufacturing facility at Nasik in Maharashtra. In the year 1984, they established R&D department at Nasik Plant. In the year 1987, they launched Ascoril.In the year 1989, the company started operations in Afghanistan, Sri Lanka, Kenya and Mauritius. In the year 1982, the company expanded th
Read More
What is the Glenmark Pharmaceuticals Ltd share price today?
The Glenmark Pharmaceuticals Ltd shares price on N/A is Rs.₹1433.25 today.
What is the Market Cap of Glenmark Pharmaceuticals Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Glenmark Pharmaceuticals Ltd is ₹40444.62 Cr. as of 22 Jul ‘24
What is the PE and PB ratio of Glenmark Pharmaceuticals Ltd?
The PE and PB ratios of Glenmark Pharmaceuticals Ltd is 27.99 and 1.74 as of 22 Jul ‘24
What is the 52 Week High and Low of Glenmark Pharmaceuticals Ltd?
The 52-week high/low is the highest and lowest price at which a Glenmark Pharmaceuticals Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Glenmark Pharmaceuticals Ltd is ₹702.05 and ₹1429.95 as of 22 Jul ‘24
What is the CAGR of Glenmark Pharmaceuticals Ltd?
Glenmark Pharmaceuticals Ltd's CAGR for 5 Years at 26.69%, 3 Years at 27.50%, 1 Year at 96.31%, 6 Month at 60.75%, 3 Month at 37.87% and 1 Month at 14.33%.
What is the shareholding pattern of Glenmark Pharmaceuticals Ltd?
The shareholding pattern of Glenmark Pharmaceuticals Ltd is as follows:
Promoters - 46.65 %
Institutions - 34.95 %
Public - 18.41 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
